welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).

expertly curated content related to this topic
-
Chemo: (Hair) Loss & Mane (Thinning)https://www.youtube.com/watch?v=TaGRE_J5...
-
What Foods Are OK to Eat After J-pouch Surgery?The j-pouch procedure (for which the te...
-
Ostomy: Diet and Nutrition GuideThis guide provides some basic informati...
-
Frank A. Sinicrope, MDInterests: Colorectal cancer prevention...
-
Bonnies Diary May 08https://jtvcancersupport.com/embed/47453...
-
The J-Pouch Group Dietary GuidelinesGood nutrition plays an essential role i...
-
Sulindac for Periampullary Polyps in FAP PatientsBACKGROUND : Gastro-duodenal polyps deve...